Mizuho raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $40 from $39 and keeps an Outperform rating on the shares. The firm updated the company’s model to reflect the Q4 report. Corbus remains on track for three data updates in 2026, the analyst tells investors in a research note. Mizuho says that with the shares trading at or near Corbus’ cash levels, it sees a favorable risk/reward ahead of multiple upcoming data catalysts.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- 3 Best Stocks to Buy Today, 4/3/2026, According to Top Analysts
- Corbus Pharmaceuticals files $300M mixed securities shelf
- Corbus Pharmaceuticals price target raised to $57 from $53 at Oppenheimer
- Corbus Pharmaceuticals: Advancing Best-in-Class Nectin-4 ADC and Emerging Obesity Franchise Support Buy Rating
- Corbus: Buy Rating Backed by CRB-701 Oncology Potential, Obesity Pipeline Catalysts, and Cash Runway Into 2028